The AACR Annual Meeting 2019 features the theme “Integrative Cancer Science • Global Impact • Individualized Patient Care.” That theme provided the structure for Monday’s plenary session, when cancer researchers representing three continents, four cancer types, and diverse areas of interest took the stage.Read More
Cancer patient advocates take on many roles in their communities. They may go out to churches to promote the benefits of cancer screening, lead patient and survivor support groups, or offer a patient’s perspective on review panels that evaluate research grants. Many times, an experience with cancer pushes people to accept advocacy roles to fill some unmet need or simply to give back.
All of these efforts were on display at this year’s American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in New Orleans Nov. 2-5. Opening the conference, 10 patient survivors and caregivers of various ethnicities and types of cancers took to the stage to describe how cancer has changed them and what cancer research has given them personally.Read More
When Michael Lawing was diagnosed with stage 3 renal cell carcinoma in 1997, he knew almost nothing about the disease.
Neither did his local urologist in rural North Carolina.
Within three years, Lawing’s cancer metastasized. His local doctor referred him to a specialist in Charlotte. Under his care, Lawing began a clinical trial of an immunotherapeutic drug. His cancer stabilized. Over the past two decades, he has experienced several recurrences of cancer, but a steady stream of newly approved treatments, most recently the immunotherapeutic Opdivo (nivolumab), have kept his disease under control. He is currently monitored with quarterly CT scans, but is taking no additional medication and experiences no symptoms or side effects.Read More
Last year, the U.S. Food and Drug Administration approved 15 new anticancer therapeutics. More groundbreaking treatments are on the way. Despite this progress, cancer still has a disproportionate impact on disadvantaged and minority groups.Read More
The U.S. Latino population surged 243 percent from 1980 to 2010. But in the same time span, the Latino physician work force dropped from 135 to 105 physicians per 100,000, according to a study by the Center for the Study of Latino Health and Culture at the University of California, Los Angeles.
This decline is alarming. It means that the growing Latino population does not get culturally competent care needed to improve patient health outcomes.Read More
Patient enrollment in clinical trials has long been on the minds of oncologists and researchers. In 1990, fewer than 3 percent of patients were enrolled in clinical trials—which spurred then president-elect of the American Cancer Society, Walter Lawrence Jr., MD, to write an editorial calling for more concerted efforts. More than 25 years later, clinical trial participation hovers around 5 percent.Read More
Yesterday, the American Association for Cancer Research (AACR) joined the American Cancer Society (ACS), the American Society of Clinical Oncology (ASCO), and the National Cancer Institute (NCI) in releasing a joint position statement to guide the future of cancer health disparities research.Read More
Guest Post by William G. Nelson, MD, PhD
Editor-in-Chief, Cancer Today
Nearly 1.7 million new cancer cases and roughly 600,000 cancer deaths are expected in the United States in 2017. The good news …
Lesbian, gay, bisexual, and transgender (LGBT) people may be at increased risk of certain cancers.Read More